FrancophonIA/ELRC3.0 huggingface dataset:
English: The choice of EVOTAZ in adult patients should be based on individual viral resistance testing and the patient's treatment history (see section 5.1).
Slovenian: Izbira zdravila EVOTAZ pri odraslih bolnikih mora temeljiti na osnovi testiranja odpornosti virusa in anamneze predhodnega zdravljenja pri vsakem posameznem bolniku (glejte poglavje 5.1).
English: The mechanism of interaction between atazanavir and tenofovir DF is unknown.
Slovenian: Mehanizem interakcije med atazanavirjem in tenofovirjem DF ni znan.
English: If the combination is needed, the recommended dose of rifabutin is 150 mg 3 times per week on set days (for example Monday-Wednesday-Friday).
Slovenian: Če je kombinirano zdravljenje potrebno, je priporočeni odmerek rifabutina 150 mg 3-krat na teden na določene dneve (na primer ponedeljek-sreda-petek).
English: This effect on serum creatinine, leading to a decrease in the estimated creatine clearance, should be taken into consideration when EVOTAZ is administered to patients in whom the estimated creatinine clearance is used to guide aspects of their clinical management, including adjusting doses of co-administered medicinal products.
Slovenian: Ta učinek na koncentracije kreatinina v serumu, ki privede do zmanjšanja ocenjenega kreatininskega očistka, je treba upoštevati, če se zdravilo EVOTAZ predpisuje bolnikom, pri katerih se vrednost ocenjenega kreatininskega očistka uporablja za usmerjanje kliničnega zdravljenja, vključno s prilagajanjem odmerkov sočasno uporabljenih zdravil.
English: Grade 3 or 4 elevation of total bilirubin was noted in 37% (6% Grade 4).
Slovenian: Zvišanje vrednosti celokupnega bilirubina stopnje 3 ali 4 so zabeležili pri 37 % bolnikov (stopnje 4 pri 6 %).
English: In clinical studies, atazanavir has been shown to induce dyslipidaemia to a lesser extent than comparators.
Slovenian: V kliničnih študijah so ugotovili, da atazanavir povzroča dislipidemijo v manjši meri kot primerjalna zdravila.
English: Atazanavir binds to both alpha-1-acid glycoprotein (AAG) and albumin to a similar extent (89% and 86%, respectively, at 1,000 ng/ml).
Slovenian: Atazanavir se v podobnem obsegu veže na alfa-1-kisli glikoprotein (AAG) in albumin (89 % na prvega in 86 % na drugega pri 1.000 ng/ml).
English: The film-coated tablet should be swallowed whole and must not be chewed, broken, cut or crushed.
Slovenian: Tablete se ne sme žvečiti, lomiti, rezati ali drobiti.
English: It is normally used in combination with other anti-HIV medicines to help control your HIV infection.
Slovenian: Običajno se predpisuje v kombinaciji z drugimi zdravili za zdravljenje okužbe z virusom HIV za nadzor okužbe z virusom HIV.
English: A long-term carcinogenicity study of cobicistat in rats revealed tumourigenic potential specific for this species that is regarded as of no relevance for humans.
Slovenian: Dolgoročna študija kancerogenosti kobicistata pri podganah je pokazala tumorogeni potencial, specifičen za to vrsto, ki pa se smatra za nepomembnega za človeka.
English: If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment.
Slovenian: Če opazite kakršne koli simptome okužbe ali druge simptome, na primer mišično oslabelost, oslabelost, ki se najprej pojavi v dlaneh in stopalih in nato širi proti trupu, palpitacije (hitro ali nepravilno utripanje srca), tremor ali hiperaktivnost, zaradi potrebnega zdravljenja nemudoma obvestite zdravnika.
English: The percentage of subjects with baseline viral loads >100,000 copies/ml was 39.7%.
Slovenian: Odstotek bolnikov z izhodiščnim virusnim bremenom > 100.000 kopij/ml je bil 39,7 %.
English: Resistance levels to atazanavir ranged from 3.5- to 29-fold without evidence of phenotypic cross resistance to other PIs.
Slovenian: Raven odpornosti proti atazanavirju se je gibala v razponu od 3,5- do 29-kratne brez znakov fenotipske navzkrižne odpornosti proti drugim zaviralcem proteaz.
English: b See section Description of selected adverse reactions for more details.
Slovenian: b Za podrobnosti glejte Opis izbranih neželenih učinkov.
English: For the treatment of erectile dysfunction, it is recommended that when co-administered with EVOTAZ, sildenafil should be used with caution at reduced doses of 25 mg every 48 hours; tadalafil should be used with caution at reduced doses of 10 mg every 72 hours; vardenafil should be used with caution at reduced doses of no more than 2.5 mg every 72 hours.
Slovenian: Priporočila za zdravljenje erektilne disfunkcije pri sočasni uporabi zdravila EVOTAZ: sildenafil je treba uporabljati previdno v zmanjšanih odmerkih 25 mg na vsakih 48 ur; tadalafil je treba uporabljati previdno v zmanjšanih odmerkih 10 mg na vsakih 72 ur; vardenafil je treba uporabljati previdno v zmanjšanih odmerkih, ki ne presegajo 2,5 mg na vsakih 72 ur.
English: Cobicistat has no antiviral activity.
Slovenian: Kobicistat nima protivirusne aktivnosti.
English: Caution should be used with medicinal products known to induce PR prolongations.
Slovenian: Pri uporabi zdravil, ki povzročajo podaljšanje intervala PR, je potrebna previdnost.
English: Serum cholesterol and glucose were minimally to mildly increased in rats but not in mice or dogs.
Slovenian: Vrednosti serumskega holesterola in glukoze so se pri podganah zvišale minimalno do blago, pri miših in psih pa se te vrednosti niso zvišale.
English: EVOTAZ and dolutegravir can be used without dose adjustments.
Slovenian: Zdravilo EVOTAZ in dolutegravir se lahko uporabljata brez prilagoditve odmerkov.
English: EVOTAZ film-coated tablets are supplied in bottles of 30 tablets.
Slovenian: EVOTAZ filmsko obložene tablete so na voljo v plastenkah s 30 tabletami.
English: Randomisation was stratified by screening HIV-1 RNA level (≤100,000 copies/ml or >100,000 copies/ml).
Slovenian: Randomizacija je bila razslojena glede na presejalne vrednosti HIV-1 RNA (≤ 100.000 kopij/ml ali > 100.000 kopij/ml).
English: Quetiapine Lurasidone
Slovenian: Kvetiapin Lurasidon
English: Ciclosporin Tacrolimus Sirolimus
Slovenian: Ciklosporin Takrolimus Sirolimus
English: ANTICOAGULANTS Warfarin
Slovenian: ANTIKOAGULANSI Varfarin
English: The safety and efficacy of atazanavir have not been established in patients with significant underlying liver disorders.
Slovenian: Varnost in učinkovitost atazanavirja pri bolnikih s pomembnimi osnovnimi boleznimi jeter nista bili dokazani.
English: It is not known whether atazanavir administered to the mother during pregnancy will exacerbate physiological hyperbilirubinaemia and lead to kernicterus in neonates and infants.
Slovenian: Ni znano, ali lahko atazanavir, če ga jemljejo nosečnice, poslabša fiziološko hiperbilirubinemijo in pri novorojenčkih in dojenčkih povzroči ikterus možganskih jeder.
English: Clinical and laboratory monitoring for hyperbilirubinaemia is recommended.
Slovenian: Priporočamo klinično in laboratorijsko nadziranje hiperbilirubinemije.
English: In patients with pre-existing conduction problems (second degree or higher atrioventricular or complex bundle-branch block), EVOTAZ should be used with caution and only if the benefits exceed the risk (see section 5.1).
Slovenian: Pri bolnikih z obstoječimi motnjami prevajanja (atrioventrikularni blok druge ali višje stopnje ali kompleksni kračni blok) je treba zdravilo EVOTAZ uporabljati previdno in le, če korist odtehta tveganje (glejte poglavje 5.1).
English: Potential for increased alfuzosin concentrations which can result in hypotension.
Slovenian: Možnost povečanja koncentracij alfuzosina in posledičen pojav hipotenzije.
English: Among the 21 subjects, 3 developed the emtricitabine-associated resistance substitution M184V.
Slovenian: Od 21 bolnikov so 3 bolniki razvili z emtricitabinom povezano rezistenčno substitucijo M184V.
English: What you need to know before you take EVOTAZ
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo EVOTAZ
English: EVOTAZ should be administered 2 hours before or 1 hour after antacids or buffered medicinal products.
Slovenian: Zdravilo EVOTAZ je treba uporabljati 2 uri pred ali 1 uro po uporabi antacida ali zdravila, ki vsebuje pufer.
English: In the group receiving atazanavir 300 mg co-administered with ritonavir 100 mg, evaluable genotypic data was available for all 19 virologic failures (5%, 19/348).
Slovenian: V skupini, ki je prejemala atazanavir v odmerku 300 mg skupaj z ritonavirjem v odmerku 100 mg, so bili na voljo ovrednoteni genotipski podatki za vseh 19 viroloških neuspehov (5 %, 19/348).
English: if you have type A or B haemophilia if you have problems with your kidneys or require haemodialysis.
Slovenian: če imate hemofilijo tipa A ali B. če imate težave z ledvicami ali se zdravite s hemodializo.
English: Data are not available to make recommendations regarding the use of EVOTAZ with other oral contraceptives.
Slovenian: Ni podatkov, da bi lahko podali priporočila o uporabi zdravila EVOTAZ skupaj z drugimi peroralnimi kontraceptivi.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/15/1025/001-002
Slovenian: EU/1/15/1025/001-002
English: The recommendations shown in Table 1 are based on either drug interaction trials of unboosted atazanavir, atazanavir boosted with ritonavir, cobicistat or predicted interactions due to the expected magnitude of the interaction and potential for serious adverse reactions or loss of therapeutic effect of EVOTAZ.
Slovenian: Priporočila, navedena v tabeli 1, temeljijo bodisi na preskušanjih interakcij z atazanavirjem brez okrepitve, atazanavirjem, okrepljenim z ritonavirjem ali s kobicistatom, ali predvidenih interakcijah zaradi pričakovanega obsega interakcije in možnosti pojava resnih neželenih učinkov ali izgube terapevtskega učinka zdravila EVOTAZ.
English: Patients co-infected with hepatitis B and/or hepatitis C virus
Slovenian: Bolniki, sočasno okuženi z virusom hepatitisa B in/ali hepatitisa C
English: The compound selectively inhibits the virus-specific processing of viral Gag-Pol proteins in HIV-1 infected cells, thus preventing formation of mature virions and infection of other cells.
Slovenian: V z virusom HIV-1 okuženih celicah selektivno zavira virusno specifične beljakovine Gag-Pol, kar prepreči nastanek zrelih virionov in s tem okužbo drugih celic.
English: Table 2: Tabulated summary of adverse reactions
Slovenian: Tabela 2: Tabelarični seznam neželenih učinkov
English: You can still pass on HIV to other people when taking this medicine, although the risk is lowered by effective antiretroviral therapy.
Slovenian: Med jemanjem tega zdravila lahko še vedno okužbo z virusom HIV prenesete na druge, čeprav učinkovito protiretrovirusno zdravljenje to tveganje zmanjša.
English: ANTIPSYCHOTICS Pimozide
Slovenian: ANTIPSIHOTIKI Pimozid
English: Although this study presented some limitations (i.e., unbound drug concentrations not studied), results suggested that the atazanavir pharmacokinetic parameters were decreased by 30% to 50% in patients undergoing haemodialysis compared to patients with normal renal function.
Slovenian: Študija ima sicer nekaj omejitev (npr. niso vrednotili koncentracij nevezanega zdravila), vendar pa rezultati kažejo, da se, v primerjavi z bolniki z normalnim delovanjem ledvic, pri bolnikih, ki se zdravijo s hemodializo, farmakokinetični parametri atazanavirja zmanjšajo za 30 % do 50 %.
English: Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART).
Slovenian: Čeprav je vzrokov verjetno več (vključno z uporabo kortikosteroidov, uživanjem alkohola, hudo imunosupresijo, višjim indeksom telesne mase), so o primerih osteonekroze poročali zlasti pri bolnikih z napredovalo boleznijo HIV in/ali dolgotrajno izpostavljenostjo kombiniranemu protiretrovirusnemu zdravljenju.
English: If EVOTAZ is co-administered with parenteral midazolam, it should be done in an intensive care unit (ICU) or similar setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation.
Slovenian: Če se zdravilo EVOTAZ uporablja skupaj s parenteralnim midazolamom, ga je treba uporabljati v enoti za intenzivno nego ali podobnih okoliščinah, ki zagotavljajo skrben klinični nadzor in možnost ustreznega zdravniškega ukrepanja v primeru zavore dihanja in/ali podaljšane sedacije.
English: If alternatives cannot be used, its use should only take place after medical evaluation and under close monitoring by your doctor for corticosteroid side effects.
Slovenian: Kadar ni mogoče uporabiti drugih zdravil, se lahko uporabljajo le po zdravniškem pregledu in ob natančnem zdravniškem spremljanju glede pojava neželenih učinkov, povezanih s kortikosteroidi.
English: EVOTAZ is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults without known mutations associated with resistance to atazanavir (see sections 4.4 and 5.1).
Slovenian: Zdravilo EVOTAZ je v kombinaciji z drugimi protiretrovirusnimi zdravili indicirano za zdravljenje odraslih bolnikov, okuženih z virusom HIV-1, brez znanih mutacij, povezanih z odpornostjo proti atazanavirju (glejte poglavji 4.4 in 5.1).
English: Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis jirovecii pneumonia.
Slovenian: Ustrezni primeri so citomegalovirusni renitis, generalizirane in/ali žariščne okužbe z mikobakterijami in pljučnica, povzročena s Pneumocystis jirovecii.
English: Based on these data and because cobicistat is not expected to have a significant impact on the pharmacokinetics of NRTIs, the co-administration of EVOTAZ with these medicinal products is not expected to significantly alter the exposure of the co-administered medicinal products.
Slovenian: Na osnovi teh podatkov in ker pomembnejšega vpliva kobicistata na farmakokinetiko NRTI-jev ne pričakujemo, pri sočasni uporabi zdravila EVOTAZ s temi zdravili ne pričakujemo, da bi se izpostavljenost sočasno uporabljenim zdravilom pomembneje spremenila.
English: The median baseline plasma HIV-1 RNA was 4.81 log10 copies/ml (range: 3.21-6.44).
Slovenian: Mediana izhodiščna vrednost HIV-1 RNA v plazmi je bila 4,81 log10 kopij/ml (razpon: 3,21-6,44).
English: The potential for PR prolongation should be considered in cases of overdose (see section 4.9).
Slovenian: V primeru prevelikega odmerjanja je treba upoštevati možnost podaljšanja intervala PR (glejte poglavje 4.9).
English: Alternative forms of contraception (non-hormonal) should be considered (see section 4.5).
Slovenian: Razmisliti je treba o drugih (nehormonskih) oblikah kontracepcije (glejte poglavje 4.5).
English: You must not take EVOTAZ with certain medicines.
Slovenian: Zdravila EVOTAZ ne smete jemati skupaj z nekaterimi drugimi zdravili.
English: Endothelin Receptor Antagonists
Slovenian: Antagonisti endotelinskih receptorjev
English: Co-administration of EVOTAZ and tenofovir alafenamide 25 mg for treatment of HBV infection is not recommended
Slovenian: Sočasna uporaba zdravila EVOTAZ in alafenamidtenofovirata v odmerku 25 mg za zdravljenje okužbe s HBV ni priporočljiva.
English: Particular caution should be used when prescribing EVOTAZ in association with medicinal products which have the potential to increase the QT interval and/or in patients with pre-existing risk factors (bradycardia, long congenital QT, electrolyte imbalances (see sections 4.8 and 5.3).
Slovenian: Posebna previdnost je potrebna pri predpisovanju zdravila EVOTAZ skupaj z zdravili, ki lahko podaljšajo interval QT, in/ali bolnikih z že obstoječimi dejavniki tveganja (bradikardija, prirojeno podaljšanje intervala QT, neravnovesje elektrolitov (glejte poglavji 4.8 in 5.3).
English: Co-administration of EVOTAZ and hormonal contraceptives should be avoided.
Slovenian: Sočasni uporabi zdravila EVOTAZ in hormonskih kontraceptivov se je treba izogibati.
English: EVOTAZ contains two active substances: atazanavir, an antiviral (or antiretroviral) medicine.
Slovenian: Zdravilo EVOTAZ vsebuje dve učinkovini: atazanavir, ki deluje proti virusom (ali retrovirusom).
English: If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered.
Slovenian: Če se pri takšnih bolnikih pojavijo znaki poslabšanja bolezni jeter, je treba razmisliti o prekinitvi ali opustitvi zdravljenja.
English: The median terminal plasma half-life of cobicistat following administration of cobicistat is approximately 3-4 hours.
Slovenian: Mediani končni razpolovni čas kobicistata v plazmi po uporabi kobicistata znaša približno 3-4 ure.
English: Animal studies do not indicate harmful effects of cobicistat on fertility.
Slovenian: Študije na živalih ne kažejo škodljivih vplivov kobicistata na plodnost.
English: In long-term carcinogenicity studies of atazanavir in mice and rats, an increased incidence of benign hepatic adenomas was seen in female mice only.
Slovenian: V dolgoročnih študijah kancerogenosti atazanavirja pri miših in podganah so večjo pojavnost benignih jetrnih adenomov odkrili samo pri mišjih samicah.
English: The recommended dose of EVOTAZ is one tablet once daily taken orally with food (see section 5.2).
Slovenian: Priporočeni odmerek zdravila EVOTAZ je ena tableta enkrat na dan. Bolnik jo vzame peroralno skupaj s hrano (glejte poglavje 5.2).
English: If switching from atazanavir boosted with ritonavir to EVOTAZ, caution is required during the first two weeks of treatment with EVOTAZ, particularly if doses of any concomitantly administered medicinal products have been titrated or adjusted during use of ritonavir as a pharmacoenhancer (see section 4.5).
Slovenian: Če se zdravljenje z atazanavirjem z okrepitvijo z ritonavirjem zamenja za zdravljenje z zdravilom EVOTAZ, je prva dva tedna zdravljenja z zdravilom EVOTAZ potrebna previdnost, še posebej, če je bil odmerek katerega koli sočasno uporabljenega zdravila titriran ali prilagojen na osnovi uporabe ritonavirja kot stopnjevalca farmakokinetike (glejte poglavje 4.5).
English: There is no specific antidote for overdose with EVOTAZ.
Slovenian: Za preveliko odmerjanje zdravila EVOTAZ ni specifičnega antidota.
English: The lowest dose of digoxin should initially be prescribed.
Slovenian: Zdravljenje z digoksinom je treba uvesti v najmanjšem odmerku.
English: Discontinued study drug due to other reasons and last available HIV-1 RNA <50 copies/mle
Slovenian: Prekinitev uporabe študijskega zdravila zaradi drugih razlogov in zadnja razpoložljiva vrednost HIV-1 RNA < 50 kopij/mle
English: PDE5 inhibitors used for the treatment of erectile dysfunction
Slovenian: Uporaba zaviralcev PDE5 za zdravljenje erektilne disfunkcije
English: Desacetyl-diltiazem Cmin ↑121%
Slovenian: Dezacetil-diltiazem Cmin ↑121%
English: How to take EVOTAZ 4.
Slovenian: Kako jemati zdravilo EVOTAZ 4.
English: Virologic success
Slovenian: Virološki neuspehc
English: Protease inhibitors: EVOTAZ in combination with other protease inhibitors is not recommended because co-administration may not provide adequate protease inhibitor exposure.
Slovenian: Zaviralci proteaz: Uporaba zdravila EVOTAZ v kombinaciji z drugimi zaviralci proteaz ni priporočljiva, saj pri sočasni uporabi morda ne bo dosežena zadostna izpostavljenost zaviralcu proteaz.
English: 25-O-desacetyl-rifabutin: AUC: ↑525% Cmax: ↑384% Cmin: ↑394%
Slovenian: 25-O-dezacetil-rifabutin: AUC: ↑525% Cmax: ↑384% Cmin: ↑394%
English: Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to CART.
Slovenian: Poročali so o primerih osteonekroze, še posebej pri bolnikih s splošno znanimi dejavniki tveganja, napredovalo boleznijo HIV ali dolgotrajno izpostavljenostjo kombiniranemu protiretrovirusnemu zdravljenju.
English: HIV-1 RNA <50 copies/ml
Slovenian: Virološki uspeh HIV-1 RNA < 50 kopij/ml
English: In some patients with advanced HIV infection (AIDS) and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started.
Slovenian: Pri nekaterih bolnikih z napredovalo okužbo z virusom HIV (AIDS-om) in predhodno oportunistično okužbo se lahko kmalu po začetku zdravljenja okužbe z virusom HIV pojavijo znaki in simptomi vnetja, povezani s prejšnjimi okužbami.
English: Patients with previous liver dysfunction or patients with chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Slovenian: Pri bolnikih s predhodnimi okvarami delovanja jeter ali bolnikih s kroničnim aktivnim hepatitisom so okvare jeter med kombiniranim protiretrovirusnim zdravljenjem pogostejše, zato je takšne bolnike treba nadzirati v skladu s standardno prakso.
English: Stevens-Johnson syndromea,b, vesiculobullous rash, eczema, vasodilatation
Slovenian: Stevens-Johnsonov sindroma,b, vezikulobulozen izpuščaj, ekcem, vazodilatacija
English: Atazanavir is an azapeptide HIV-1 protease inhibitor (PI).
Slovenian: Atazanavir je azapeptidni zaviralec proteaz (PI; “protease inhibitor”) virusa HIV-1.
English: The median baseline CD4+ cell count was 352 cells/mm3 (range: 1-1455) and 16.9% had CD4+ cell counts ≤200 cells/mm3.
Slovenian: Mediano izhodiščno število celic CD4+ je bilo 352 celic/mm3 (razpon: 1-1.455), 16.9 % bolnikov pa je imelo število celic CD4+ ≤200 celic/mm3.
English: Following oral administration of [14C]cobicistat, 99% of circulating radioactivity in plasma was unchanged cobicistat.
Slovenian: Po peroralni uporabi [14C]kobicistata je 99 % cirkulirajoče radioaktivnosti v plazmi odpadlo na nespremenjeni kobicistat.
English: These are listed under Do not take EVOTAZ, at the start of section 2.
Slovenian: Ta zdravila so navedena na začetku poglavja 2 pod naslovom Ne jemljite zdravila EVOTAZ.
English: Some people will need special care before or while taking EVOTAZ.
Slovenian: Pri nekaterih bolnikih je pred uvedbo zdravljenja ali med zdravljenjem z zdravilom EVOTAZ potrebna posebna previdnost.
English: Atazanavir exhibits anti-HIV-1 (including all clades tested) and anti-HIV-2 activity in cell culture.
Slovenian: Atazanavir na celičnih kulturah kaže anti-HIV-1 aktivnost (vključno z vsemi testiranimi sevi) in antiHIV-2 aktivnost.
English: Two percent of patients treated with atazanavir experienced concurrent Grade 3-4 ALT/AST and Grade 3-4 total bilirubin elevations.
Slovenian: Dva odstotka bolnikov, ki so se zdravili z atazanavirjem, sta imela sočasno zvišane vrednosti ALT/AST stopnje 3-4 in celokupnega bilirubina stopnje 3-4.
English: Voxilaprevir AUC : ↑331%
Slovenian: Voksilaprevir AUC: ↑331%
English: Cobicistat AUC ↔ Cobicistat Cmax ↔ Cobicistat Cmin ↑232%
Slovenian: Kobicistat AUC ↔ Kobicistat Cmax ↔ Kobicistat Cmin ↑232%
English: Raltegravir AUC ↑72% Raltegravir Cmax ↑53% Raltegravir C12hr ↑95%
Slovenian: Raltegravir AUC ↑72% Raltegravir Cmax ↑53% Raltegravir C12ur ↑95%
English: Itraconazole, like ketoconazole, is a potent inhibitor as well as a substrate of CYP3A4.
Slovenian: Itrakonazol je, podobno kot ketokonazol, močan zaviralec in tudi substrat za CYP3A4.
English: The recommended adult dose of EVOTAZ is one tablet daily by mouth and with food, in combination with other anti-HIV medicines.
Slovenian: Priporočeni odmerek zdravila EVOTAZ za odrasle je ena tableta enkrat na dan v kombinaciji z drugimi zdravili za zdravljenje okužbe z virusom HIV.
English: PDE5 Inhibitors
Slovenian: Zaviralci PDE5